ClinicalTrials.gg
CompletedNCT01537640Updated Dec 6, 2013

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

A Phase 1 interventional study of SAR231893 (REGN668) DP1 and SAR231893 (REGN668) DP2 in Healthy, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-06.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Primary Objective:

To determine and compare the pharmacokinetic (PK) profiles of 2 different SAR231893 (REGN668) drug products after administration of a single subcutaneous (SC) dose

Secondary Objective:

To determine and compare the safety and tolerability of the 2 SAR231893 (REGN668) drug products after administration of a single SC dose

Read the detailed description

The duration of the study for each subject is 8-11 weeks broken down as follows:

  • Screening: 2 to 21 days,
  • Treatment: 1 day (2 overnight stays at the study site),
  • Follow-up: up to 2 months after dosing.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between 18 and 45 years of age

Exclusion criteria

Exclusion criteria:

  • Presence or history of drug or allergic disease
  • History or presence of dermatological disorders
  • Fever or persistent chronic or active recurring infection requiring treatment within 4 weeks prior to screening, or history of frequent recurrent infections
  • Prior opportunistic infections within 6 months before inclusion
  • History or presence of listeriosis or tuberculosis
  • Any vaccination within 3 months (1 month for influenza vaccine) before inclusion
  • Any biologics given within 4 months before inclusion
  • Recent history of a parasitic infection or travel to a parasitic endemic area within 6 months prior to screening

The above information is not intended to contain all considerations relevant to a subject's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SAR231893 (REGN668) Drug Product (DP) 1

    SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection

    Biological: SAR231893 (REGN668) DP1

  • Experimental
    SAR231893 (REGN668) Drug Product (DP) 2

    SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection

    Biological: SAR231893 (REGN668) DP2

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of serum concentrations of SAR231893 (REGN668)

    Time frame: Up to 57 Days

Secondary outcomes

  1. Pain evaluation at injection site using Visual Analog Scale (VAS)

    Time frame: Up to 8 Days

  2. Erythema at injection site by measuring diameter

    Time frame: Up to 8 Days

  3. Edema at injection site by measuring diameter

    Time frame: Up to 8 Days

  4. Number of participants experiencing adverse events

    Time frame: Up to 57 Days

07

Study locations

1 site
  • Investigational Site Number 840001
    Daytona Beach, Florida 32117, United States
08

References and documents

Publications

  • Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2020 Aug;9(6):742-755. doi: 10.1002/cpdd.798. Epub 2020 Apr 29. PubMed 32348036 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2012
First posted
Feb 23, 2012
Start
Feb 2012
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Last update
Dec 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01537640
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 23, 2012
Start date
Feb 2012
Primary completion
Jul 2012
Completion
Jul 2012
Last update
Dec 6, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion